DNA methylation and the HOXC6 paradox in prostate cancer

Cancers

Volumn 3, Issue 4, 2011, Pages 3714-3725

  Vinarskaja, Anna ^a   Yamanaka, Masanori ^a   Ingenwerth, Marc ^a   Schulz, Wolfgang A ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

DNA methylation; Epigenetic silencing; Homeobox transcription factors; Prostate cancer; WNT signaling

Indexed keywords

HOMEOBOX TRANSCRIPTION FACTOR HOXC6; HOMEODOMAIN PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER RELAPSE; CNTN1 GENE; DKK3 GENE; DNA METHYLATION; EPIGENETICS; GENE; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC TRANSCRIPTION; HOX GENE; HOXC6 GENE; HUMAN; HUMAN TISSUE; MALE; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WIF1 GENE;

EID: 84055190514     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers3043714     Document Type: Article

References (35)

1. Nelson, W.G.; de Marzo, A.M.; Yegnasubramanian, S. Epigenetic alterations in human prostate cancers. Endocrinology 2009, 150, 3991-4002.
2. Schulz, W.A.; Hoffmann, M.J. Epigenetic mechanisms in the biology of prostate cancer. Semin. Cancer Biol. 2009, 19, 172-180.
3. Hoque, M.O. DNA methylation changes in prostate cancer: Current developments and future clinical implementation. Expert Rev. Mol. Diagn. 2009, 9, 243-257.
4. Perry, A.S.; Watson, R.W.; Lawler, M.; Hollywood, D. The epigenome as a therapeutic target in prostate cancer. Nat. Rev. Urol. 2010, 7, 668-680.
5. Pfeifer, G.P.; Rauch, T.A. DNA methylation patterns in lung carcinomas. Semin. Cancer Biol. 2009, 19, 181-187.
6. Shah, N.; Sukumar, S. The Hox genes and their roles in oncogenesis. Nat. Rev. Cancer 2010, 10, 361-371.
7. Waltregny, D.; Alami, Y.; Clausse, N.; de Leval, J.; Castronovo, V. Overexpression of the homeobox gene HOXC8 in human prostate cancer correlates with loss of tumor differentiation. Prostate 2002, 50, 162-169.
8. Economides, K.D.; Capecchi, M.R. Hoxb13 is required for normal differentiation and secretory function of the ventral prostate. Development 2003, 130, 2061-2069.
9. Hombría, J.C.; Lovegrove, B. Beyond homeosis-HOX function in morphogenesis and organogenesis. Differentiation 2003, 71, 461-476.
10. Miller, G.J.; Miller, H.L.; van Bokhoven, A.; Lambert, J.R.; Werahera, P.N.; Schirripa, O.; Lucia, M.S.; Nordeen, S.K. Aberrant HOXC expression accompanies the malignant phenotype in human prostate. Cancer Res. 2003, 63, 5879-5888.
11. Huang, L.; Pu, Y.; Hepps, D.; Danielpour, D.; Prins, G.S. Posterior Hox gene expression and differential androgen regulation in the developing and adult rat prostate lobes. Endocrinology 2007, 148, 1235-1245.
12. Ke, X.S.; Qu, Y.; Rostad, K.; Li, W.C.; Lin, B.; Halvorsen, O.J.; Haukaas, S.A.; Jonassen, I.; Petersen, K.; Goldfinger N, et al. Genome-wide profiling of histone h3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis. PLoS One 2009, 4, e4687.
13. Shen, M.M.; Abate-Shen, C. Molecular genetics of prostate cancer: New prospects for old challenges. Genes Dev. 2010, 24, 1967-2000.
14. Ramachandran, S.; Liu, P.; Young, A.N.; Yin-Goen, Q.; Lim, S.D.; Laycock, N.; Amin, M.B.; Carney, J.K.; Marshall, F.F.; Petros, J.A.; Moreno, C.S. Loss of HOXC6 expression induces apoptosis in prostate cancer cells. Oncogene 2005, 24, 188-198.
15. McCabe, C.D.; Spyropoulos, D.D.; Martin, D.; Moreno, C.S. Genome-wide analysis of the homeobox C6 transcriptional network in prostate cancer. Cancer Res. 2008, 68, 1988-1996.
16. Bibikova, M.; Chudin, E.; Arsanjani, A.; Zhou, L.; Garcia, E.W.; Modder, J.; Kostelec, M.; Barker, D.; Downs, T.; Fan J.B, et al. Expression signatures that correlated with Gleason score and relapse in prostate cancer. Genomics 2007, 89, 666-672.
17. Moreno, C.S. The Sex-determining region Y-box 4 and homeobox C6 transcriptional networks in prostate cancer progression: Crosstalk with the Wnt, Notch, and PI3K pathways. Am. J. Pathol. 2010, 176, 518-527.
18. Wissmann, C.; Wild, P.J.; Kaiser, S.; Roepcke, S.; Stoehr, R.; Woenckhaus, M.; Kristiansen, G.; Hsieh, J.C.; Hofstaedter, F.; Hartmann, A, et al. WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J. Pathol. 2003, 201, 204-212.
19. Florl, A.R.; Steinhoff, C.; Müller, M.; Seifert, H.H.; Hader, C.; Engers, R.; Ackermann, R.; Schulz, W.A. Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br. J. Cancer 2004, 91, 985-994.
20. Joesting, M.S.; Perrin, S.; Elenbaas, B.; Fawell, S.E.; Rubin, J.S.; Franco, O.E.; Hayward, S.W.; Cunha, G.R.; Marker, P.C. Identification of SFRP1 as a candidate mediator of stromal-toepithelial signaling in prostate cancer. Cancer Res. 2005, 65, 10423-10430.
21. Lodygin, D.; Epanchintsev, A.; Menssen, A.; Diebold, J.; Hermeking, H. Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res. 2005, 65, 4218-4227.
22. Kawano, Y.; Kitaoka, M.; Hamada, Y.; Walker, M.M.; Waxman, J.; Kypta, R.M. Regulation of prostate cell growth and morphogenesis by Dickkopf-3. Oncogene 2006, 25, 6528-6537.
23. Zenzmaier, C.; Untergasser, G.; Hermann, M.; Dirnhofer, S.; Sampson, N.; Berger, P. Dysregulation of Dkk-3 expression in benign and malignant prostatic tissue. Prostate 2008, 68, 540-547.
24. Kawano, Y.; Diez, S.; Uysal-Onganer, P.; Darrington, R.S.; Waxman, J.; Kypta, R.M. Secreted Frizzled-related protein-1 is a negative regulator of androgen receptor activity in prostate cancer. Br. J. Cancer. 2009, 100, 1165-1174.
25. Costa, V.L.; Henrique, R.; Ribeiro, F.R.; Carvalho, J.R.; Oliveira, J.; Lobo, F.; Teixeira, M.R.; Jerónimo, C. Epigenetic regulation of Wnt signaling pathway in urological cancer. Epigenetics 2010, 5, 343-351.
26. Yee, D.S.; Tang, Y.; Li, X.; Liu, Z.; Guo, Y.; Ghaffar, S.; McQueen, P.; Atreya, D.; Xie, J.; Simoneau AR, et al. The Wnt inhibitory factor 1 restoration in prostate cancer cells was associated with reduced tumor growth, decreased capacity of cell migration and invasion and a reversal of epithelial to mesenchymal transition. Mol. Cancer 2010, 9, 162.
27. Eckerich, C.; Zapf, S.; Ulbricht, U.; Müller, S.; Fillbrandt, R.; Westphal, M.; Lamszus, K. Contactin is expressed in human astrocytic gliomas and mediates repulsive effects. GLIA 2006, 53, 1-12.
28. Su, J.L.; Yang, C.Y.; Shih, J.Y.; Wei, L.H.; Hsieh, C.Y.; Jeng, Y.M.; Wang, M.Y.; Yang, P.C.; Kuo, M.L. Knockdown of contactin-1 expression suppresses invasion and metastasis of lung adenocarcinoma. Cancer Res. 2006, 66, 2553-2561.
29. Veeck, J.; Wild, P.J.; Fuchs, T.; Schuffler, P.J.; Hartmann, A.; Knüchel, R.; Dahl, E. Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancer. BMC Cancer 2009, 9, 217.
30. Schulz, W.A.; Alexa, A.; Jung, V.; Hader, C.; Hoffmann, M.J.; Yamanaka, M.; Fritzsche, S.; Wlazlinski, A.; Müller, M.; Lengauer T, et al. Factor interaction analysis for chromosome 8 and DNA methylation alterations highlights innate immune response suppression and cytoskeletal changes in prostate cancer. Mol. Cancer 2007, 6, 14.
31. Chan, S.L.; Cui, Y.; van Hasselt, A.; Li, H.; Srivastava, G.; Jin, H.; Ng, K.M.; Wang, Y.; Lee, K.Y.; Tsao G.S, et al. The tumor suppressor Wnt inhibitory factor 1 is frequently methylated in nasopharyngeal and esophageal carcinomas. Lab. Invest. 2007, 87, 644-650.
32. Marques, R.B.; Dits, N.F.; Erkens-Schulze, S.; van Weerden, W.M.; Jenster, G. Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models. PLoS One 2010, 5, e13500.
33. Li, X.; Nie, S.; Chang, C.; Qiu, T.; Cao, X. Smads oppose Hox transcriptional activities. Exp. Cell Res. 2006, 312, 854-864.
34. Norris, J.D.; Chang, C.Y.; Wittmann, B.M.; Kunder, R.S.; Cui, H.; Fan, D.; Joseph, J.D.; McDonnell, D.P. The homeodomain protein HOXB13 regulates the cellular response to androgens. Mol. Cell 2009, 35, 405-416.
35. Wang, D.; Garcia-Bassets, I.; Benner, C.; Li, W.; Su, X.; Zhou, Y.; Qiu, J.; Liu, W.; Kaikkonen, M.U.; Ohgi KA, et al. Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature 2011, 474, 390-394.